Media
On this page, we highlight information of particular relevance for the media, including news, events and featured information for journalists interested in the evaluation and safety monitoring of medicines in the European Union.
For more information and details relevant for media, see our News and events section.
For enquiries from media, please contact the EMA press office.
Featured information for journalists
EMA's 2024 annual report
EMA's 2024 annual report offers insights into key initiatives and priority areas that guided our work in 2024. Explore the interactive digital report or read the PDF version with figures and statistics on EMA's regulatory procedures and activities.
Human medicines: highlights of 2024
In 2024, EMA recommended 114 medicines for marketing authorisation. Of these, 46 had a new active substance which had never been authorised in the European Union before.
Veterinary medicines: highlights of 2024
In 2024, EMA recommended 25 medicines for marketing authorisation. Of these, two had a new active substance.
European medicines agencies network strategy to 2028
The strategy equips the European medicines regulatory network to respond to change and address challenges such as public health emergencies and threats, including antimicrobial resistance.
EMA communication activities: 2024 survey results
We asked stakeholders for feedback on our external communication activities via a bi-annual survey disseminated in May 2024. The results are available in a newly-published report. They help us to establish baselines and targets to measure progress, analyse trends and address areas for improvement.
Video: Working for every patient in Europe
Watch our short video for a quick and easy explanation of who EMA is and what it does. (video in English, with subtitles in 24 different languages).
Latest news
PRAC agrees on a communication to healthcare professionals on injectable tranexamic acid medicines
ICMRA elects new chair in Amsterdam
#HealthNotHype social media campaign aims to expand audience reach of public health messages
Brinsupri significantly reduces and delays the occurrence of pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis
Higher rate of death and disease complications in recent trials means benefit-risk balance no longer favourable
Two new medicines recommended for approval; another eight medicines recommended for extension of their therapeutic indications